Cetrorelix Evidence Guide
Cetrorelix (Cetrotide) is FDA-approved as a standard component of controlled ovarian stimulation protocols in IVF, with Phase 3 data supporting its efficacy in preventing premature LH surges. It is an established clinical tool with a well-defined use case, reliable dosing, and a strong safety record in reproductive medicine.
Our Take
Cetrorelix (Cetrotide) is FDA-approved as a standard component of controlled ovarian stimulation protocols in IVF, with Phase 3 data supporting its efficacy in preventing premature LH surges. It is an established clinical tool with a well-defined use case, reliable dosing, and a strong safety record in reproductive medicine.
- Best for
- IVF ovarian stimulation protocols, LH surge prevention, GnRH antagonist research
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 0.25mg subcutaneous daily (starting stimulation day 5 or 6) or 3mg single-dose protocol
Benefits and Evidence
- Premature LH Surge Prevention (IVF): Level A, includes human evidence - Effectively prevents premature ovulation during IVF stimulation. Meta-analyses show comparable pregnancy rates to GnRH agonist long protocols with shorter treatment duration and fewer injections.
- Reduced OHSS Risk: Level A, includes human evidence - GnRH antagonist protocols are associated with significantly lower risk of ovarian hyperstimulation syndrome (OHSS) compared to agonist protocols, as they allow GnRH agonist triggering instead of hCG.
- Rapid Gonadotropin Suppression: Level A, includes human evidence - Produces significant LH suppression within 8 hours and near-complete suppression within 24 hours. Faster onset than any GnRH agonist protocol.
Side Effects and Warnings
- Injection site reactions (redness, swelling)
- Headache
- Nausea
- OHSS (lower incidence than agonist protocols)
- Ovarian enlargement
- Not for use in women with severe renal impairment
- Hypersensitivity reactions including anaphylaxis have been reported
- Must be used under supervision of fertility specialist
Research Dosage References
- <strong>Subcutaneous</strong> - 0.25 mg daily - Daily starting day 5-7 of ovarian stimulation until trigger day - Standard IVF flexible protocol. Initiation based on follicle size or fixed day of stimulation. Continue until hCG or GnRH agonist trigger.
- <strong>Subcutaneous</strong> - 3 mg single dose - Single injection on stimulation day 7 - Single-dose protocol. If trigger not given within 4 days, add 0.25 mg daily until trigger. Less commonly used than daily protocol.
Mechanism of Action
Cetrorelix acts as a competitive GnRH receptor antagonist: 1. Competitive receptor blockade: Occupies the GnRH receptor without activating it, preventing endogenous GnRH from binding and triggering gonadotropin release. 2. Immediate suppression: Unlike agonists, there is no initial stimulatory phase. LH and FSH levels decline within hours of administration. 3. Dose-dependent duration: Single 3 mg dose provides suppression for approximately 4 days; daily 0.25 mg doses provide continuous suppression. 4. Rapid reversibility: Upon discontinuation, pituitary function recovers within 1-2 days as the drug is cleared and endogenous GnRH can again access receptors.
Legal Status
FDA-approved prescription medication (Cetrotide). Prescription only. Not a controlled substance.
Primary Sources
- GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis. Human Reproduction Update, 2016.
- Cetrorelix for preventing premature LH surges in women undergoing ovarian stimulation. Human Reproduction, 1997.